Search This Blog

Thursday, August 1, 2024

Merus Q2 results, update

 Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients

– First patients dosed in phase 3 trial evaluating petosemtamab monotherapy in 2/3L HNSCC, phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 2L mCRC, and phase 2 trial evaluating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC

– Based on the Company’s current operating plan, existing cash, cash equivalents, including successful public offering raising $460M gross proceeds, and marketable securities expected to fund Merus’ operations into 2028

https://www.biospace.com/merus-announces-financial-results-for-the-second-quarter-2024-and-provides-business-update

VDH: Harris Is Recycling The 2020 Democrat Campaign

 by Victor Davis Hanson via American Greatness,

Joe Biden won the 2020 presidential election through a successful tripartite subterfuge.

One, Biden never really campaigned.

His handlers rightly assumed that the more the public and the media saw a debilitated Biden in the flesh, the less they would want him as president.

So, the Biden campaign used the COVID lockdowns to ensure that Biden stayed safe in his basement office.

Biden strategically distanced himself from disinterested journalists, using COVID as an excuse to avoid public appearances. It allowed him to run a 19th-century, front-porch sort of virtual campaign.

In his place, the liberal media, Democratic grandees, and the billionaire donor class served as Biden campaign surrogates—vastly outspending, out-advertising, and out-lawyering the underfunded incumbent Trump.

Second, again using COVID as a pretext, well-funded Democratic legal teams altered the voting laws during early 2020 in key swing states to encourage non-Election Day voting.

For the first time, majorities in many key states voted by mail-in/absentee ballots and during weeks of early voting.

We now know why the left was so motivated to push through radical balloting changes that were otherwise impossible prior to 2020 but have been mostly institutionalized since.

Non-Election Day ballots outnumbered Election Day ballots. They were far more likely to be cast by Democrats. And as the number of such ballots soared, the traditional rejection rate of non-Election Day ballots prior to 2020 fell—even as registrars were swamped.

Once obscure terms such as ballot harvesting and ballot curing became mainstream.

Ballot deadlines were extended. There was lax enforcement of incorrect ballot names and addresses or auditing the registrars’ rolls.

Rich liberal entities, such as Mark Zuckerberg and his $419 million in 2020 cash infusions, sought to absorb the work of state registrars. His aim was to “improve” voter turnout through partisan “assistance”—from funding drop boxes to monitoring non-Election Day ballots.

Three, in 2020, the enervated left-wing Joe Biden was reconstructed as a vigorous moderate “ol’ Joe Biden from Scranton.”

Biden’s stealth script was to provide a temperate veneer to the new hard-left Democratic Party.

His 2020 campaign claimed Joe was for “unity” and “moderation”—even as it camouflaged an otherwise extremist neo-socialist agenda to be implemented after November.

Can the Democrats repeat that winning formula for Kamala Harris in 2024?

Only partly.

Even without the excuse of COVID, Harris certainly will not agree to unscripted, ad hoc interviews with non-partisan journalists.

She is unable to speak extemporaneously and off the teleprompter without appearing childish.

Her handlers will ensure few opportunities for Harris to burst into cackling or to stream her puerile musings about yellow school buses or kindergarten geography.

Yet the third element of Biden’s 2020 strategy will be difficult to replicate.

The Bay Area leftist Harris—unlike the Biden of the 1980s and 1990s—never had any reputation, feigned or not, of being a “centrist” or “moderate.”

Her entire political career was one of pandering either to leftist Democrat voters in 2020 or ultra-liberal Californians in her statewide races.

She is on record of opposing fracking and off-shore drilling, private health care, border enforcement, and the traditional close U.S. relationship with Israel.

She proudly promoted the radical new green deal, defunding police forces, mandatory buybacks of private guns, and mass amnesties.

She gratuitously championed the swindler Jussie Smollett and his fraudulent claims of being a victim of systemic racism.

During the horrendous riots of 2020, she sought to raise bail for violent rioters and looters that had been arrested.

On CBS, she egged on the 2020 protests that had already turned violent with deaths, law enforcement injuries, arson, and mass looting—despite the pathetic efforts of partisan fact-checkers to claim otherwise.

Harris gushed of the turmoil:

“They’re not going to stop. This is a movement, I’m telling you. They’re not going to stop, and everyone beware, because they’re not going to stop. They’re not going to stop before Election Day in November and they’re not going to stop after Election Day. They’re not going to let up and they should not, and we should not.”

What did Harris mean by “beware?”

Was the BLM- and Antifa-led mayhem really just a “movement?”

Why boast that the turmoil might be endless—both before and after Election Day?

And why connect the massive disruptions to the upcoming Election Day—unless she believes that unrest in the streets could weaken the election chances of the then incumbent president?

In sum, Harris, like Biden, is certainly capable of running a remote stealth campaign.

She will surely take advantage of 2020’s revolution in non-Election Day balloting.

Yet, unlike Biden, Harris has no credible moderate veneer—only an unapologetic radical past and a corpus of hard-left boasts.

So, 2024 will hinge on whether Republicans will expose Harris’s lifelong, hard-left ideology and extremist agendas.

She is a poor substitute for the successful bait-and-switch 2020 con of “ol’ Joe Biden,” the fake moderate “uniter” from Scranton.

https://www.zerohedge.com/political/vdh-harris-recycling-2020-democrat-campaign

Obama's Fourth Term: Bidenomics & Neofascism On Steroids

 by James Rickards via DailyReckoning.com,

Americans have just passed through the most eventful and tumultuous four weeks in memory.

The only comparisons are 9/11, the fall of the Berlin Wall in 1989, the Watergate/Vietnam days of the 1970s, the riots and assassinations in the 1960s and the Cuban Missile Crisis.

First, we had Joe Biden’s face-plant debate performance on June 27 when he looked like a corpse and spoke in a demented way.

Then came the attempted assassination of Donald Trump on July 13 in Butler, Pennsylvania (which killed one and wounded two others).

This was followed by the Republican National Convention and nomination of J.D. Vance on July 15, the decision of Joe Biden to withdraw from the presidential race on July 21 and finally the coronation of Queen Kamala Harris in the following days (more on Harris below).

Any one of these stories would be huge news in any election cycle, but to have five such events in less than four weeks is a lot to process, let alone fully comprehend.

Far More Questions Than Answers

We know some of what happened, but much is being covered up by the government. Was Biden set up to fail at the debate as a prelude to Kamala? Was the Secret Service passively involved in the assassination by letting it happen? Did the shooter truly act alone, or did he receive assistance? Was Joe Biden threatened with a coup d’etat in the form of leaks about his health and removal from office under the 25th amendment if he didn’t step aside?

At this point, we do not have answers to these and many other questions. Still, the questions themselves are important. They’re one way to keep the record open. We should not rest until we have answers.

Questions are a tool to keep pressure on public officials and not allow them to sweep this all under the rug. The Democrats running the White House and the FBI are screeching about protecting “democracy” and offering “transparency,” yet they are the greatest threats to both.

Let’s keep the questions alive and not allow the official cover-up to prevail. Perhaps if Trump wins the election, we’ll get to the bottom of some of this in due course.

Let’s move on to Kamala Harris…

Queen Kamala

The canonization of Kamala Harris by mainstream media and the collateral gaslighting of the American people have begun in earnest.

She was a failed border czar, but now the media pretend that never happened and she was just some kind of goodwill ambassador to Guatemala. Whatever. We don’t need the media to tell us who Kamala is and what she would do.

We know already.

She’s an empty pantsuit with a low IQ and a weird ability to give long explanations that make absolutely no sense, punctuated by cackles.

Can you imagine what serious foreign leaders like Vladimir Putin and Xi Jinping must think when they hear her speak? They probably can’t believe that such a person could possibly become leader of the most powerful nation in the world.

Harris is already pandering to the pro-Palestinian, anti-Israeli base of the Democratic Party.

Kamala Shuns Netanyahu

Benjamin Netanyahu, the prime minister of Israel, gave an address to a joint meeting of Congress on July 24. His purpose was to explain why Israel went to war with Hamas, how Israel is conducting that war and Israel’s plans for an eventual end to the conflict.

One would think those facts and forecasts would be well-known to members of Congress, but that gives them too much credit. Members of Congress get their information through a haze of biased and misleading media (like the rest of us) and have to work hard to develop reliable sources and objective assessments to understand what’s going on.

Many people don’t want to hear the facts, but here they are: The war began in response to the greatest one-day massacre of Jews since the Holocaust. It will continue until the last Hamas terrorist is dead or enough have been killed to render Hamas impotent as a fighting and terrorist force.

That may take a few more months. Once that mission is completed, Israel will establish some type of interim government in Gaza with only limited autonomy for the people there in order to prevent the reemergence of a new Hamas.

It’s All About Wokeism

Israel needs continued support from the U.S., in particular weapons systems including air defense and ammunition and intelligence sharing, in order to defeat Hamas. Addressing Congress, Netanyahu offered a blunt assessment of pro-Hamas demonstrators in the United States, especially on campuses and the streets of major cities.

He made it clear that these protesters are not humanitarians, but are simply supporters of terrorism, rape and murder. There’s room for disagreement, but it was refreshing to hear a political leader speak in such candid and honest terms.

Americans are used to the platitudes and cliches of U.S. politicians and rarely get to hear such a clear summary of the situation.

By the way, it might be a stretch to call the forum a “joint” meeting of Congress. Many Democrats boycotted the session, including VP Kamala Harris, who was to have a prominent role as president of the Senate.

Her cowardice and that of her colleagues reveal most Democrats for who they really are — supporters of terror and haters of Israel. They see everything through the prism of wokeism, which holds that there’s always an oppressed group and an oppressor who’s stomping on them.

In their view, Israel is the oppressor and Palestinians are the oppressed. It doesn’t matter what atrocities Hamas or other terrorist organizations commit because the greater injustice is Israeli “oppression,” which is much more imagined than real.

Obama’s Fourth Term

Anyway, here’s what you do need to know as investors: A Harris victory means more of the same. It’s been argued, correctly, that Biden’s presidency has really been Obama’s third term. Key Obama personnel have been behind the scenes, calling the shots the entire time.

Kamala’s an Obama puppet, and even though Biden and Harris can’t stand each other, they both carried the Obama baton. What that means is more government dysfunction. It means more of the Green New Scam, including attacks on big oil and gas and a hold on new leases for drilling on federal lands.

It means a wider war in Ukraine with a risk of escalation to a nuclear war. It means higher taxes and more regulation. It also means slower economic growth, not by design, but as a result of excessive government debt relative to GDP.

Furthermore, it means expanded weaponization of the Department of Justice, FBI and Department of Homeland Security. You’ll have continued open borders resulting in lower wages for all Americans and widespread diseases like whooping cough and tuberculosis from the unvaccinated aliens.

More government censorship will be the norm. This list goes on, but no guesswork is required. This will be Bidenomics and neofascism on steroids.

If Harris wins, investment winners would be Big Tech, Big Pharma, China and the Green New Scammers. Investment losers would be oil and natural gas, defense and mining.

If Trump wins, it would be the opposite. Guess which I’m hoping for.

https://www.zerohedge.com/political/obamas-fourth-term-bidenomics-neofascism-steroids

Alphatec cut to Equal Weight by Morgan Stanley

 From Overweight

https://finviz.com/quote.ashx?t=ATEC&p=d

ALX Oncology Falls On Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer

 ALX Oncology Holdings Inc. (NASDAQ:ALXO) released topline data from its Phase 2 ASPEN-06 clinical trial.

ASPEN-06 is evaluating evorpacept in combination with trastuzumab, Cyramza (ramucirumab), and paclitaxel (collectively, TRP) against TRP alone for HER2-positive gastric/GEJ cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.

The ASPEN-06 study is testing a new treatment combination for advanced stomach and gastroesophageal cancer in patients who have already undergone other treatments. This combination includes a drug named evorpacept, added to a standard therapy mix.

Results so far show that this new combination helps patients respond better and for a longer duration compared to the standard therapy alone.

In the full intent-to-treat population (N=127), the addition of evorpacept to TRP demonstrated an overall response rate (ORR) of 40.3% compared to the TRP control ORR of 26.6%.

The company released prespecified interim Phase 2 data from its ASPEN-06 trial in October 2023.

The data showed a confirmed overall response rate (ORR) of 52% for evorpacept in combination with trastuzumab + Cyramza + paclitaxel compared to 22% for the control group of trastuzumab + Cyramza + paclitaxel.

In patients with fresh HER2-positive biopsies (n=48), evorpacept plus TRP demonstrated an ORR of 54.8% compared to 23.1% for the TRP control.

The median duration of response (DOR) in the evorpacept arm was 15.7 months compared to the TRP control of 7.6 months.

Secondary endpoints of progression-free survival (PFS) and overall survival (OS) were immature at the time of analysis.

Evorpacept, in combination with TRP, was generally well tolerated and consistent with TRP control.

“By meeting our clinically meaningful and pre-specified threshold of greater than 10% difference in response between the evorpacept treatment and control arms, these new data validate the mechanism of action and potential clinical utility of evorpacept for patients. Notably, this is now the first CD47 blocker to demonstrate clinical benefit and a well-tolerated safety profile in a randomized trial,” said Sophia Randolph, chief medical officer at ALX Oncology.

The FDA has granted Fast Track designation to evorpacept for the second-line treatment of patients with HER2-positive gastric or GEJ carcinoma. The FDA and European Commission have also granted Orphan Drug Designation for this indication.

Omnicell beats, ups guidance

 Results exceed previously issued second quarter guidance across all metrics

Total revenues of $277 million

GAAP net income per diluted share of $0.08

Non-GAAP net income per diluted share of $0.51

Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance

Omnicell Conference Call Information

Omnicell will hold a conference call today, Thursday, August 1, 2024 at 8:30 a.m. ET to discuss second quarter 2024 financial results. The conference call can be monitored by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3278878. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell’s website at http://ir.omnicell.com/events-and-presentations/.

https://www.businesswire.com/news/home/20240801890749/en/

Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 141.3% in July

 Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a large increase in short interest in July. As of July 15th, there was short interest totalling 52,600 shares, an increase of 141.3% from the June 30th total of 21,800 shares. Approximately 8.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 0.0 days.

https://www.defenseworld.net/2024/07/28/dermata-therapeutics-inc-nasdaqdrma-short-interest-up-141-3-in-july.html